We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Santaris Pharma’s HIF-1 Alpha Antagonist Begins Second Phase 1 Study against Solid Tumours and Lymphoma

News   Nov 05, 2007

 
Santaris Pharma’s HIF-1 Alpha Antagonist Begins Second Phase 1 Study against Solid Tumours and Lymphoma
 
 
 

RELATED ARTICLES

Human Blood-Brain Barrier Chip Aids Development of Brain-targeting Drugs

News

A microfluidic organ chip model of the human blood-brain barrier, that recapitulates in vivo barrier functions, offers a new preclinical tool for development of brain-targeting therapeutics.

READ MORE

Researchers Examine the Potential Misuse of Anti-anxiety Medication

News

There is concern about the misuse of the sedative anti-anxiety medication alprazolam because of the “high” it can create. A study found that non-medical use of alprazolam in the United Kingdom is a significant issue,

READ MORE

Your Gut Bacteria May Determine How Well You Respond to Drugs

News

Yale researchers identified human gut microbes that metabolize over 150 therapeutic drugs, a finding that highlights the role bacteria play in determining how well individuals respond to medications.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE